Hardening of Respiratory Syncytial Virus Inclusion Bodies by Cyclopamine Proceeds through Perturbation of the Interactions of the M2-1 Protein with RNA and the P Protein.
M2-1-P interaction
RSV
antiviral mechanism
cyclopamine
inclusion bodies
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
08 Sep 2023
08 Sep 2023
Historique:
received:
24
06
2023
revised:
20
08
2023
accepted:
04
09
2023
medline:
29
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
Respiratory syncytial virus (RSV) RNA synthesis takes place in cytoplasmic viral factories also called inclusion bodies (IBs), which are membrane-less organelles concentrating the viral RNA polymerase complex. The assembly of IBs is driven by liquid-liquid phase separation promoted by interactions between the viral nucleoprotein N and the phosphoprotein P. We recently demonstrated that cyclopamine (CPM) inhibits RSV multiplication by disorganizing and hardening IBs. Although a single mutation in the viral transcription factor M2-1 induced resistance to CPM, the mechanism of action of CPM still remains to be characterized. Here, using FRAP experiments on reconstituted pseudo-IBs both in cellula and in vitro, we first demonstrated that CPM activity depends on the presence of M2-1 together with N and P. We showed that CPM impairs the competition between P and RNA binding to M2-1. As mutations on both P and M2-1 induced resistance against CPM activity, we suggest that CPM may affect the dynamics of the M2-1-P interaction, thereby affecting the relative mobility of the proteins contained in RSV IBs. Overall, our results reveal that stabilizing viral protein-protein interactions is an attractive new antiviral approach. They pave the way for the rational chemical optimization of new specific anti-RSV molecules.
Identifiants
pubmed: 37762166
pii: ijms241813862
doi: 10.3390/ijms241813862
pmc: PMC10531356
pii:
doi:
Substances chimiques
cyclopamine
ZH658AJ192
RNA
63231-63-0
Veratrum Alkaloids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Agence Nationale de la Recherche
ID : ANR-19-CE18-0012-01
Organisme : Agence Nationale de la Recherche
ID : ANR-21-CE15-0030-02
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
J Virol. 2015 Apr;89(7):3484-96
pubmed: 25568210
Virology. 1993 Jul;195(1):243-7
pubmed: 8317099
Biochemistry. 2012 Oct 16;51(41):8100-10
pubmed: 22978633
Int J Mol Sci. 2021 Feb 03;22(4):
pubmed: 33546457
Lancet. 2017 Sep 2;390(10098):946-958
pubmed: 28689664
Int J Mol Sci. 2020 Nov 28;21(23):
pubmed: 33260713
Arch Virol. 2016 Aug;161(8):2351-60
pubmed: 27216929
Structure. 2020 Sep 1;28(9):979-990.e4
pubmed: 32697936
Elife. 2014 May 19;3:e02674
pubmed: 24842877
Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19678-82
pubmed: 17164337
J Biol Chem. 2022 Sep;298(9):102337
pubmed: 35931116
Nat Methods. 2012 Jun 28;9(7):690-6
pubmed: 22743774
Front Immunol. 2022 Aug 09;13:985622
pubmed: 36016945
Pathogens. 2022 Nov 11;11(11):
pubmed: 36422576
J Biomol NMR. 2016 Oct;66(2):111-124
pubmed: 27663422
Vet Res. 2023 Apr 17;54(1):36
pubmed: 37069656
Angew Chem Int Ed Engl. 2010 Mar 15;49(12):2238-41
pubmed: 20186894
Biomol NMR Assign. 2011 Oct;5(2):237-9
pubmed: 21523439
Methods Mol Biol. 2012;815:241-52
pubmed: 22130996
mBio. 2020 Sep 22;11(5):
pubmed: 32963000
J Virol. 2020 Oct 27;94(22):
pubmed: 32878896
Nat Commun. 2017 Sep 15;8(1):563
pubmed: 28916773
PLoS Pathog. 2021 Oct 14;17(10):e1009926
pubmed: 34648608
Vet Res. 2007 Mar-Apr;38(2):153-80
pubmed: 17257568
mBio. 2018 Nov 13;9(6):
pubmed: 30425144
Vet Immunol Immunopathol. 1989 Sep;22(2):145-60
pubmed: 2530685
Assay Drug Dev Technol. 2011 Aug;9(4):342-53
pubmed: 21812660
J Virol. 1999 Jan;73(1):251-9
pubmed: 9847328
J Biol Chem. 2017 Feb 10;292(6):2120-2131
pubmed: 28031463
J Mol Biol. 2018 Mar 16;430(6):777-792
pubmed: 29414675
J Virol. 2009 Jul;83(13):6363-74
pubmed: 19386701
Trends Biochem Sci. 2023 Mar;48(3):229-243
pubmed: 36272892
Nucleic Acids Res. 2016 Jul 8;44(W1):W449-54
pubmed: 27131374
Vet Microbiol. 2017 Jul;206:59-68
pubmed: 28024854
Proc Natl Acad Sci U S A. 2014 Jan 28;111(4):1580-5
pubmed: 24434552
Protein Sci. 2021 Jan;30(1):70-82
pubmed: 32881101
PLoS Pathog. 2012;8(5):e1002734
pubmed: 22675274
Trends Microbiol. 2022 Dec;30(12):1217-1231
pubmed: 35902318
Nature. 2021 Jul;595(7868):596-599
pubmed: 34234347
Sci Rep. 2016 May 19;6:25806
pubmed: 27194388
PLoS Pathog. 2018 Feb 28;14(3):e1006920
pubmed: 29489893
Methods Mol Biol. 2017;1563:243-267
pubmed: 28324613